1056-SORATRAM (#1236)
Laufzeit: 01.01.2021 - 31.12.2040
Kurzfassung
Cross-institutional, prospective, open label, single group basket study of combinedCRAF and MEK inhibition in advanced-stage malignancies harboring BRAF mutationswith impaired kinase activity
